Publications

5900 Results

A Randomized Phase II Study of Capmatinib plus Osimertinib with or without Ramucirumab in Patients with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study S1900G)

Authors
Goldberg S;Redman MW;Camidge DR;Minichiello K;Highleyman L;Patel JD;Stinchcombe T;Bradley JD;Brahmer JR;Borghaei H;Gray JE;Waqar SN;Reckamp KL;Herbst RS;Kelly K;Ross HJ
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); TIP TPS8677 poster
Year
2026
Research Committee(s)
Lung
Study Number(s)
S1900G

Immune-Related Adverse Event Severity and Clinical Outcomes with Immune Checkpoint Inhibitor Immunotherapy in Participants with Non–Small Cell Lung Cancer: Analysis of the Lung MAP sub-studies S1400A, S1400I, S1400F, and S1800A

Authors
Tseng D;Moon J;Bazhenova L;Leighl NB;Borghaei H;Dragnev KH;Baik CS;Langer CJ;Neal JW;Gandara DR;Kelly K;Gray JE;Herbst RS;Waqar SN
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 8572 poster
Year
2026
Research Committee(s)
Lung
Study Number(s)
S1400A, S1400F, S1400I, S1800A

A Phase II study of amivantamab hyaluronidase in MET amplification-positive stage IV or recurrent non-small cell lung cancer (Lung-MAP Sub-Study)

Authors
Rolfo C;Redman MW;Gadgeel SM;Minichiello K;Highleyman L;Waqar SN;Herbst RS;Stinchcombe T;Higgins KA;Brahmer JR;Reckamp KL;Borghaei H;Gray JE;Gandara DR
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs TPS8680 TIP poster
Year
2026
Research Committee(s)
Lung
Study Number(s)
S1900J

Simplified Trials, Broader Reach: Lessons from SWOG S2302 Pragmatica-Lung

Authors
Kahlil M
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); pub only e23016 WITHDRAWN
Year
2026
Research Committee(s)
Lung
Study Number(s)
S2302

The Association of Baseline Fatigue and Severe Cancer Treatment Toxicity Persists by Comorbid Conditions: A Pooled Analysis

Authors
Caplan M;Unger JM;Till C;Fisch MJ;Henry NL;Accordino MK;Hershman DL
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il);
abs 11036 poster
Year
2026

Prevalence and Trends in Rural Patient Enrollment in SWOG Cancer Clinical Trials, 1992-2022

Authors
Okado I;Till C;Osarogiagbon RU;Doolittle GC;Hershman DL;Unger JM
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il);
abs 11068 poster
Year
2026
Research Committee(s)
Cancer Care Delivery

Clinical, Sociodemographic, Geographic, and Health Contributors to Variation in Overall Survival Across Randomized Cancer Trials

Authors
Unger JM;Till C;Osarogiagbon RU;Hershman DL;LeBlanc ML
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il);
pub only e23080 WITHDRAWN
Year
2026
Research Committee(s)
Cancer Care Delivery

A Risk Prediction Model for Severe, Life-Threatening, and Fatal Treatment-Related Toxicity

Authors
Unger JM;Henry NL;Fisch MJ;Hershman DL
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 12143 poster
Year
2026

External Validation of the locked ArteraAI Breast MMAI model for Prognosis and Chemotherapy Benefit Prediction in Postmenopausal, Node-Positive, Hormone Receptor-Positive Breast Cancer Patients: Analysis of SWOG S8814

Authors
Speers CW;Piehler A;Meisner A;Zhang J;Barlow WE;Zwerink W;Pusztai L;Sharma P;Chao CY;Thompson AM;Godwin AK;Albain KS;Griffin JR;Rae JM
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 107 oral
Year
2026
Research Committee(s)
Breast
Study Number(s)
SWOG-8814

DART (NCI/SWOG S1609): Comprehensive Results from Dual Checkpoint Inhibition with CTLA-4 and PD-1 Blockade in Rare Cancers

Authors
Patel SP;Othus M;Chae YK;Azenkot T;Alviz C;Threlkel S;Haymaker C;Streicher HZ;Magner CM;Chen HX;Sharon E;Ryan CW;Blanke CD;Kurzrock R
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 2502 oral
Year
2026
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609